Cargando…
In silico drug repurposing in COVID-19: A network-based analysis
The SARS-CoV-2 pandemic is a worldwide public health emergency. Despite the beginning of a vaccination campaign, the search for new drugs to appropriately treat COVID-19 patients remains a priority. Drug repurposing represents a faster and cheaper method than de novo drug discovery. In this study, w...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier Masson SAS.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8316014/ https://www.ncbi.nlm.nih.gov/pubmed/34358753 http://dx.doi.org/10.1016/j.biopha.2021.111954 |
_version_ | 1783729804292390912 |
---|---|
author | Sibilio, Pasquale Bini, Simone Fiscon, Giulia Sponziello, Marialuisa Conte, Federica Pecce, Valeria Durante, Cosimo Paci, Paola Falcone, Rosa Norata, Giuseppe Danilo Farina, Lorenzo Verrienti, Antonella |
author_facet | Sibilio, Pasquale Bini, Simone Fiscon, Giulia Sponziello, Marialuisa Conte, Federica Pecce, Valeria Durante, Cosimo Paci, Paola Falcone, Rosa Norata, Giuseppe Danilo Farina, Lorenzo Verrienti, Antonella |
author_sort | Sibilio, Pasquale |
collection | PubMed |
description | The SARS-CoV-2 pandemic is a worldwide public health emergency. Despite the beginning of a vaccination campaign, the search for new drugs to appropriately treat COVID-19 patients remains a priority. Drug repurposing represents a faster and cheaper method than de novo drug discovery. In this study, we examined three different network-based approaches to identify potentially repurposable drugs to treat COVID-19. We analyzed transcriptomic data from whole blood cells of patients with COVID-19 and 21 other related conditions, as compared with those of healthy subjects. In addition to conventionally used drugs (e.g., anticoagulants, antihistaminics, anti-TNFα antibodies, corticosteroids), unconventional candidate compounds, such as SCN5A inhibitors and drugs active in the central nervous system, were identified. Clinical judgment and validation through clinical trials are always mandatory before use of the identified drugs in a clinical setting. |
format | Online Article Text |
id | pubmed-8316014 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | The Authors. Published by Elsevier Masson SAS. |
record_format | MEDLINE/PubMed |
spelling | pubmed-83160142021-07-28 In silico drug repurposing in COVID-19: A network-based analysis Sibilio, Pasquale Bini, Simone Fiscon, Giulia Sponziello, Marialuisa Conte, Federica Pecce, Valeria Durante, Cosimo Paci, Paola Falcone, Rosa Norata, Giuseppe Danilo Farina, Lorenzo Verrienti, Antonella Biomed Pharmacother Article The SARS-CoV-2 pandemic is a worldwide public health emergency. Despite the beginning of a vaccination campaign, the search for new drugs to appropriately treat COVID-19 patients remains a priority. Drug repurposing represents a faster and cheaper method than de novo drug discovery. In this study, we examined three different network-based approaches to identify potentially repurposable drugs to treat COVID-19. We analyzed transcriptomic data from whole blood cells of patients with COVID-19 and 21 other related conditions, as compared with those of healthy subjects. In addition to conventionally used drugs (e.g., anticoagulants, antihistaminics, anti-TNFα antibodies, corticosteroids), unconventional candidate compounds, such as SCN5A inhibitors and drugs active in the central nervous system, were identified. Clinical judgment and validation through clinical trials are always mandatory before use of the identified drugs in a clinical setting. The Authors. Published by Elsevier Masson SAS. 2021-10 2021-07-28 /pmc/articles/PMC8316014/ /pubmed/34358753 http://dx.doi.org/10.1016/j.biopha.2021.111954 Text en © 2021 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Sibilio, Pasquale Bini, Simone Fiscon, Giulia Sponziello, Marialuisa Conte, Federica Pecce, Valeria Durante, Cosimo Paci, Paola Falcone, Rosa Norata, Giuseppe Danilo Farina, Lorenzo Verrienti, Antonella In silico drug repurposing in COVID-19: A network-based analysis |
title | In silico drug repurposing in COVID-19: A network-based analysis |
title_full | In silico drug repurposing in COVID-19: A network-based analysis |
title_fullStr | In silico drug repurposing in COVID-19: A network-based analysis |
title_full_unstemmed | In silico drug repurposing in COVID-19: A network-based analysis |
title_short | In silico drug repurposing in COVID-19: A network-based analysis |
title_sort | in silico drug repurposing in covid-19: a network-based analysis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8316014/ https://www.ncbi.nlm.nih.gov/pubmed/34358753 http://dx.doi.org/10.1016/j.biopha.2021.111954 |
work_keys_str_mv | AT sibiliopasquale insilicodrugrepurposingincovid19anetworkbasedanalysis AT binisimone insilicodrugrepurposingincovid19anetworkbasedanalysis AT fiscongiulia insilicodrugrepurposingincovid19anetworkbasedanalysis AT sponziellomarialuisa insilicodrugrepurposingincovid19anetworkbasedanalysis AT contefederica insilicodrugrepurposingincovid19anetworkbasedanalysis AT peccevaleria insilicodrugrepurposingincovid19anetworkbasedanalysis AT durantecosimo insilicodrugrepurposingincovid19anetworkbasedanalysis AT pacipaola insilicodrugrepurposingincovid19anetworkbasedanalysis AT falconerosa insilicodrugrepurposingincovid19anetworkbasedanalysis AT noratagiuseppedanilo insilicodrugrepurposingincovid19anetworkbasedanalysis AT farinalorenzo insilicodrugrepurposingincovid19anetworkbasedanalysis AT verrientiantonella insilicodrugrepurposingincovid19anetworkbasedanalysis |